SpringWorks Therapeutics ... (SWTX)
SpringWorks Therapeutics Statistics
Share Statistics
SpringWorks Therapeutics has 74.94M shares outstanding. The number of shares has increased by 0.81% in one year.
| Shares Outstanding | 74.94M |
| Shares Change (YoY) | 0.81% |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 70.29M |
| Failed to Deliver (FTD) Shares | 302 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 13.66M, so 18.36% of the outstanding shares have been sold short.
| Short Interest | 13.66M |
| Short % of Shares Out | 18.36% |
| Short % of Float | 20.77% |
| Short Ratio (days to cover) | 8.57 |
Valuation Ratios
The PE ratio is -10.38 and the forward PE ratio is -17.73. SpringWorks Therapeutics's PEG ratio is 0.32.
| PE Ratio | -10.38 |
| Forward PE | -17.73 |
| PS Ratio | 13.98 |
| Forward PS | 3.6 |
| PB Ratio | 5.57 |
| P/FCF Ratio | -14.88 |
| PEG Ratio | 0.32 |
Enterprise Valuation
SpringWorks Therapeutics Inc. has an Enterprise Value (EV) of 2.14B.
| EV / Earnings | -8.27 |
| EV / Sales | 11.14 |
| EV / EBITDA | -7.68 |
| EV / EBIT | -7.68 |
| EV / FCF | -11.86 |
Financial Position
The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.81 |
| Quick Ratio | 3.7 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.62 |
| Cash Flow / Debt | -22.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.54% and return on capital (ROIC) is -56.88%.
| Return on Equity (ROE) | -0.54% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | -56.88% |
| Revenue Per Employee | $520,622.28 |
| Profits Per Employee | $-701,442.93 |
| Employee Count | 368 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 1.23 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -3.22% in the last 52 weeks. The beta is 0.76, so SpringWorks Therapeutics's price volatility has been higher than the market average.
| Beta | 0.76 |
| 52-Week Price Change | -3.22% |
| 50-Day Moving Average | 44.76 |
| 200-Day Moving Average | 38.66 |
| Relative Strength Index (RSI) | 51.64 |
| Average Volume (20 Days) | 2.38M |
Income Statement
In the last 12 months, SpringWorks Therapeutics had revenue of 191.59M and earned -258.13M in profits. Earnings per share was -3.48.
| Revenue | 191.59M |
| Gross Profit | 179.04M |
| Operating Income | -278.13M |
| Net Income | -258.13M |
| EBITDA | -278.13M |
| EBIT | -278.13M |
| Earnings Per Share (EPS) | -3.48 |
Balance Sheet
The company has 69.75M in cash and 7.91M in debt, giving a net cash position of 61.84M.
| Cash & Cash Equivalents | 69.75M |
| Total Debt | 7.91M |
| Net Cash | 61.84M |
| Retained Earnings | -1.15B |
| Total Assets | 587.28M |
| Working Capital | 280.48M |
Cash Flow
In the last 12 months, operating cash flow was -175.6M and capital expenditures -4.45M, giving a free cash flow of -180.05M.
| Operating Cash Flow | -175.6M |
| Capital Expenditures | -4.45M |
| Free Cash Flow | -180.05M |
| FCF Per Share | -2.43 |
Margins
Gross margin is 93.45%, with operating and profit margins of -145.17% and -134.73%.
| Gross Margin | 93.45% |
| Operating Margin | -145.17% |
| Pretax Margin | -134.73% |
| Profit Margin | -134.73% |
| EBITDA Margin | -145.17% |
| EBIT Margin | -145.17% |
| FCF Margin | -93.98% |
Dividends & Yields
SWTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.02% |
| FCF Yield | -4.84% |
Analyst Forecast
The average price target for SWTX is $74, which is 49.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $74 |
| Price Target Difference | 49.2% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 17.1 |
| Piotroski F-Score | 3 |